The estimated Net Worth of Randall L Vanderveen is at least 1.26 百万$ dollars as of 16 November 2020. Randall Vanderveen owns over 9,440 units of Mylan NV stock worth over 907,048$ and over the last 10 years he sold MYL stock worth over 0$. In addition, he makes 350,006$ as Non-Executive Independent Director at Mylan NV.
Sign up
Randall Vanderveen MYL stock SEC Form 4 insiders trading
Randall has made over 6 trades of the Mylan NV stock since 2016, according to the Form 4 filled with the SEC. Most recently he exercised 9,440 units of MYL stock worth 149,624$ on 16 November 2020.
The largest trade he's ever made was exercising 9,440 units of Mylan NV stock on 16 November 2020 worth over 149,624$. On average, Randall trades about 2,996 units every 166 days since 2015. As of 16 November 2020 he still owns at least 57,227 units of Mylan NV stock.
You can see the complete history of Randall Vanderveen stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Randall Vanderveen biography
Dr. Randall L. Vanderveen Ph.D. serves as Non-Executive Independent Director of the Company. Dr. Vanderveen was Professor of Pharmaceutical Policy and Economics, Senior Adviser to the Leonard D. Schaeffer Center of Health Policy and Economics, Director of the Margaret and John Biles Center for Leadership, and Senior Adviser to the Dean for Advancement at the School of Pharmacy, University of Southern California in Los Angeles, California from 2015 to August 2017. Dr. Vanderveen previously served as Dean, Professor and John Stauffer Decanal Chair of the USC School of Pharmacy from 2005 to 2015, where he was named “Outstanding Pharmacy Dean in the Nation” in 2013 by the American Pharmacist Association. From 1998 to 2005, he served as Dean and Professor of Pharmacy of the School of Pharmacy and the Graduate School of Pharmaceutical Sciences at Duquesne University, before which he was Assistant Dean at Oregon State University from 1988 to 1998. Dr. Vanderveen will not serve as a director of Viatris upon closing of the Combination. Dr. Vanderveen’s qualifications to serve on Mylan’s Board include, among others, his experience and expertise regarding the healthcare industry, pharmaceuticals and pharmacy practice, public healthcare policy and economics, and scientific matters.
What is the salary of Randall Vanderveen?
As the Non-Executive Independent Director of Mylan NV, the total compensation of Randall Vanderveen at Mylan NV is 350,006$. There are 10 executives at Mylan NV getting paid more, with Heather Bresch having the highest compensation of 18,509,300$.
How old is Randall Vanderveen?
Randall Vanderveen is 69, he's been the Non-Executive Independent Director of Mylan NV since 2016. There are 2 older and 10 younger executives at Mylan NV. The oldest executive at Mylan NV is Robert Cindrich, 76, who is the Non-Executive Independent Director.
What's Randall Vanderveen's mailing address?
Randall's mailing address filed with the SEC is BUILDING 4, TRIDENT PLACE, MOSQUITO WAY, , HATFIELD, HERTFORDSHIRE, X0, AL10 9UL.
Insiders trading at Mylan NV
Over the last 10 years, insiders at Mylan NV have traded over 1,861,785,794$ worth of Mylan NV stock and bought 202,008 units worth 5,767,632$ . The most active insiders traders include Laboratories Abbott Product...、Daniel Martin Jr Gallagher、Robert J Coury. On average, Mylan NV executives and independent directors trade stock every 15 days with the average trade being worth of 5,605,891$. The most recent stock trade was executed by Robert J Cindrich on 16 November 2020, trading 9,440 units of MYL stock currently worth 149,624$.
What does Mylan NV do?
Mylan NV is a pharmaceutical healthcare company. The firm engages in the development, license, manufacture, market and distribution of generic, branded generic and specialty pharmaceutical products. It operates through the following geographical segments: North America, Europe and Rest of World. The North America segment develops, manufactures, sells, and distributes pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized and cream, or ointment form. The Europe segment operates through subsidiaries in Italy, Germany, the United Kingdom, and Spain. The Rest of World segment comprises of operations in Japan, Australia, China, Brazil, Russia, India, South Africa, Middle East and South East Asia. The company was founded in 1961 and is headquartered in Hatfield, the United Kingdom.
What does Mylan NV's logo look like?
Complete history of Randall Vanderveen stock trades at Mylan NV
Mylan NV executives and stock owners
Mylan NV executives and other stock owners filed with the SEC include:
-
Heather Bresch,
Chief Executive Officer, Executive Director -
Rajiv Malik,
President, Executive Director -
Robert Coury,
Executive Chairman of the Board -
Mark Parrish,
Lead Independent Non-Executive Vice Chairman of the Board -
JoEllen Dillon,
Non-Executive Independent Director -
Neil Dimick,
Non-Executive Independent Director -
Melina Higgins,
Non-Executive Independent Director -
Sjoerd Vollebregt,
Non-Executive Independent Director -
Robert Cindrich,
Non-Executive Independent Director -
Harry Korman,
Non-Executive Independent Director -
Randall Vanderveen,
Non-Executive Independent Director -
Pauline van der Meer Mohr,
Non-Executive Independent Director -
Richard Mark,
Non-Executive Independent Director -
Melissa Trombetta,
Head of Global Investor Relations -
Joseph C Md Maroon,
Director -
Rodney L Piatt,
Director -
Paul Campbell,
See Remarks -
Laboratories Abbott Product...,
-
Kenneth Scott Parks,
Chief Financial Officer -
Wendy Cameron,
Director -
Douglas J Leech,
Director -
Daniel Martin Jr Gallagher,
Chief Legal Officer -
Anthony Mauro,
Chief Commercial Officer -
John D Sheehan,
EVP and CFO -
Laboratories Abbott Establi...,
-
Laboratories Laboratoires F...,